The approval was based on the impressive HERA (HERceptin Adjuvant) study results demonstrating that Herceptin significantly reduced the risk of death and recurrence by more than one third(34%
XP13512 demonstrated statistically significant improvements compared to placebo on both of the co-primary endpoints of the trial and was generally well-tolerated. Results from the pre-specified analysis indicate that
As a result of this decision, AstraZeneca will have its own option to acquire Merck’s interest in these non-proton pump inhibitor (non-PPI) products in the first half of
The Phase I trial, a multiple, ascending dose study conducted at several sites in the US is designed to identify pharmacologically active doses and preliminary antitumor activity as
In the study, five groups of volunteers were each administered a single dose of Solulin, with escalating dosages in the consecutive dose groups. Each dose increase was first
Theodore Zucconi, president of Pro-Pharmaceuticals, said: “This financing, together with the ‘friends and family’ private placement we recently completed, enables us to reach critical milestones for Davanat and
In the not approvable letter FDA expressed concern if the efficacy findings support clinical utility of istradefylline (KW-6002). FDA requested an overall summary of nonclinical mineralization findings. Additionally,
This double-blind, three-way cross-over study is designed to investigate the influence of EVT 302 on craving and withdrawal symptoms after short-term deprivation of cigarettes in 90 smokers. Smokers
The SARM compounds were in-licensed by Radius with the intention to develop new compounds for treatment of osteoporosis. Karo Bio has now reacquired all rights to the SARM
In connection with the financing, Jeffrey Leiden, managing director, and Scott Requadt, principal, both of Clarus Ventures, and Arthur Pappas, managing partner, Pappas Ventures, will join TyRx’s board
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.